Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta VariantsmRNA COVID-19 백신 3회 용량과 SARS-CoV-2 오미크론 및 델타 변이체로 인한 증상 감염 간의 연관성Observational Study Published on 2022-02-152022-09-11 Journal: JAMA [Category] COVID19(2023년), SARS, 변종, 임상, [키워드] 95% CI adjusted odds ratio age Analysis Assessing association Before test BNT162b2 booster dose Case-control Control controls COVID-19 COVID-19 testing COVID-19 vaccine Critical Cycle threshold value defined Delta delta variant Delta variants dose doses eligible Guidance health guidance higher odd individual less median Moderna mRNA-1273 vaccine mRNA mRNA vaccine multinomial regression multivariable National nucleic acid Odds ratio Older omicron ORF1ab outcome Pfizer Pfizer-BioNTech public health receipt reported S-gene SARS-CoV-2 SARS-COV-2 infection second dose secondary outcome seeking significantly higher stratified symptomatic SARS-CoV-2 infection tested the SARS-CoV-2 vaccination Vaccination Status vaccine dose variant variants viral genes were measured women [DOI] 10.1001/jama.2022.0470 PMC 바로가기 [Article Type] Observational Study
Performance evaluation of an automatic chemiluminescence immune platform for SARS-CoV-2 neutralizing antibody after vaccination in real worldSARS-COV-2를위한 자동 화학 발광 면역 플랫폼의 성능 평가 현실에서 예방 접종 후 항체Research Published on 2022-02-152022-09-01 Journal: BMC Infectious Diseases [Category] COVID19(2023년), Fulltext, MERS, SARS, 진단, [키워드] Adolescent BBIBP-CorV changes in Characteristics chemiluminescence China CLIA Cohort CoronaVac doses evaluated exceeded Follow-up followed by Hemolysis high correlation icterus immune immunity after vaccination immunoassays inactive injection inoculation investigated less linearity lipemia measure Neutralizing activity Neutralizing antibodies neutralizing antibody objective occurred performance Physical examination Plaque reduction neutralization test platform predominant PRNT Real world recipient recruited repeatability Result robust SARS-CoV-2 SARS-CoV-2 antibodies SARS-CoV-2 antibody SARS-CoV-2 neutralizing antibodies SARS-CoV-2 neutralizing antibody SARS-CoV-2 vaccine schedule Sensitivity and specificity Serological assay serological assays seropositive Shenzhen significantly lower Sinovac strength Trial vaccination Vaccination Status Vaccinations Vaccine Variation volunteers [DOI] 10.1186/s12879-022-07141-8 PMC 바로가기 [Article Type] Research
COVID-19 Recovery Patterns Across Alpha (B.1.1.7) and Delta (B.1.617.2) Variants of SARS-CoV-2SARS-CoV-2 변종 알파(B.1.1.7) 및 델타(B.1.617.2)의 코로나19 회복 패턴Comparative Study Published on 2022-02-142022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, [키워드] (alpha 95% CI age Alpha alpha and delta variants Alpha variant Analysis B.1.1.7 B.1.617.2 B1.1.7 B1.617.2 baseline conducted Coverage COVID-19 COVID-19 vaccine Ct values Delta delta variant difference electronic medical records hazard hazards hospital discharge Hospital stay hospital stay length indicated individuals Infection infections Interaction Length medical records National objective participant pathogenicity Patient patients pattern PCR test positive RT-PCR recovery pattern reported Research Result RT-PCR RT-PCR Ct RT-PCR test SARS-CoV-2 Sequencing Sex significantly lower Treatment vaccination Vaccination Status variant variant of SARS-CoV-2 variants variants of concern virus was performed whole genome Whole genome sequencing [DOI] 10.3389/fimmu.2022.812606 PMC 바로가기 [Article Type] Comparative Study
Post-Vaccination SARS-CoV-2 Infections among Health Workers at the University Hospital of Verona, Italy: A Retrospective Cohort SurveyArticle Published on 2022-02-102022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] Ageusia Anosmia BNT162b2 Clinical data collected conducted COVID-19 pandemic COVID-19 symptoms COVID-19-related symptoms cumulative Dyspnea Effectiveness Europe Fever Frequency Health Health surveillance health worker health workers incidence Infection infection spreading Italy less Mainz much lower offered percentage positive questionnaire reduced reductions in reported retrospective cohort study SAR-CoV-2 SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccination severity Spread subjects Surveillance survey Swab symptom severity symptomatic tested the SARS-CoV-2 United States university vaccination Vaccination Status Vaccine Verona worker York [DOI] 10.3390/vaccines10020272 PMC 바로가기 [Article Type] Article
Influence of the Delta Variant and Vaccination on the SARS-CoV-2 Viral LoadSARS-COV-2 바이러스 부하에 대한 델타 변종 및 예방 접종의 영향Article Published on 2022-02-042022-09-01 Journal: Viruses [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] age and sex Alpha assays conducted COVID-19 Delta delta variant diagnosed dose doses Evolution Host Infection infections influence lead load nasopharyngeal Patient Prospective Study reducing SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 RNA single center Symptom symptom onset Symptoms the SARS-CoV-2 Thermo Fisher university vaccination Vaccination Status variant variants Viral Viral load viral spread virus were assessed were recorded [DOI] 10.3390/v14020323 PMC 바로가기 [Article Type] Article
Comparative Effectiveness of Coronavirus Vaccine in Preventing Breakthrough Infections among Vaccinated Persons Infected with Delta and Alpha Variants델타 및 알파 변이체에 감염된 백신 접종자의 돌발 감염 예방에 대한 코로나바이러스 백신의 비교 효과Research Published on 2022-02-012022-09-10 Journal: Emerging Infectious Diseases [Category] COVID19(2023년), MERS, SARS, 변종, [키워드] acute respiratory syndrome adjusted age Alpha Alpha variant Breakthrough infection breakthrough infections Comparative coronavirus coronavirus disease coronavirus variants COVID-19 Cycle threshold value Delta delta variant Diagnosis Effectiveness Infection Logistic regression mean difference mRNA vaccine mRNA vaccines Odds ratio Patient PCR cycle PCR-positive Person Portugal Preventing preventing infection reported respiratory respiratory infections SARS-CoV-2 severe acute respiratory syndrome coronavirus 2 Sex significantly higher threshold value used data vaccination Vaccination Status Vaccine vaccine-preventable diseases variant Viral Viral load viruses zoonoses [DOI] 10.3201/eid2802.211789 PMC 바로가기 [Article Type] Research
No difference in risk of hospitalization between reported cases of the SARS-CoV-2 Delta variant and Alpha variant in Norway노르웨이에서 보고된 SARS-CoV-2 Delta 변이형과 Alpha 변이형 사이에 입원 위험에 차이가 없음Article Published on 2022-02-012022-09-11 Journal: International Journal of Infectious Diseases [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 Alpha Alpha variant aRR calculated cohort study Comorbidities conducted coronavirus disease Coronavirus disease 2019 Coronavirus-2 Delta delta variant demographic characteristics diagnosed Hospitalization Hospitalized laboratory-confirmed no difference Norway reduced risk reported risk risk ratio sampling SARS-CoV-2 Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus Support the SARS-CoV-2 vaccination Vaccination Status variant variants variants of concern [DOI] 10.1016/j.ijid.2021.12.321 PMC 바로가기 [Article Type] Article
COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence – 25 U.S. Jurisdictions, April 4-December 25, 2021델타 및 오미크론 변이형 출현 기간 동안 추가 접종 여부와 관계없이 백신 접종을 하지 않은 성인 및 완전히 예방 접종을 받은 성인의 COVID-19 발병률 및 사망률 - 25 미국 관할 구역, 2021년 4월 4일-12월 25일Article Published on 2022-01-282022-09-11 Journal: Morbidity and Mortality Weekly Report [Category] 변종, [키워드] accounted averaged B.1.1.529 B.1.617.2 booster dose booster doses cause CDC COVID-19 COVID-19 case COVID-19 illness COVID-19 vaccinations COVID-19 vaccine death death rate death rates declined Delta dose emergence groups highest Hospitalization Immunocompromised incidence rate Infection Lineage omicron Omicron variant Period Rate receipt risk SARS-CoV-2 sequenced serious COVID-19 the United State The United States United States vaccination Vaccination Status Vaccinations Vaccine Vaccine-induced immunity variant variant of SARS-CoV-2 virus was recorded with COVID-19 [DOI] 10.15585/mmwr.mm7104e2 PMC 바로가기 [Article Type] Article
SARS-CoV-2 Delta Variant Breakthrough Infection and Onward Secondary Transmission in HouseholdSARS-CoV-2 델타 변이형 돌발 감염 및 가정 내 2차 전파Article Published on 2022-01-032022-09-11 Journal: Journal of Korean medical science [Category] 변종, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Asymptomatic attack rate BNT162b2 BNT162b2 mRNA BNT162b2 mRNA COVID-19 vaccine calculated Chain Reaction characterized Clinical severity close contact confirmed case coronavirus coronavirus disease Coronavirus disease 2019 Coverage COVID-19 COVID-19 vaccine Delta delta variant Effectiveness epidemiologic feature groups household infected case infection rate isolate mass vaccination mRNA mRNA vaccine of BNT162b2 outbreak participant Participants polymerase chain polymerase chain reaction reverse transcriptase Reverse transcriptase polymerase chain reaction SAR SARS-CoV-2 SARS-CoV-2 delta SARS-CoV-2 virus second secondary secondary attack rate secondary transmission severe acute respiratory syndrome Coronavirus South Korea symptomatic case symptomatic cases the vaccine transcriptase Transmissibility vaccination vaccination rate Vaccination Status Vaccine vaccinee variant [DOI] 10.3346/jkms.2022.37.e12 PMC 바로가기 [Article Type] Article
Efficacy of Pfizer-BioNTech in SARS-CoV-2 Delta clusterSARS-CoV-2 Delta 클러스터에서 Pfizer-BioNTech의 효능Case Reports Published on 2022-01-012022-09-11 Journal: International Journal of Infectious Diseases [Category] SARS, 변종, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus B.1.617.2 BNT162b Boston case sery circulating close contact Cluster Contact tracing Coronavirus-2 COVID-19 Delta delta variant dominant dose Effectiveness event India individual International Massachusetts morbidity and mortality PCR PCR testing Pfizer-BioNTech positive Probability responsible SARS-CoV-2 second dose Sequencing Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus-2 subsequent tested Transmission USA vaccinated individual vaccinated individuals vaccination Vaccination Status Vaccine variant variant of concern [DOI] 10.1016/j.ijid.2021.10.053 PMC 바로가기 [Article Type] Case Reports